We are excited to announce the launch of our POLE-POLD1 Mutation Controls, designed to support researchers and clinicians in advancing cancer diagnostics and immunotherapy research.

About POLE-POLD1 mutations:
POLE-POLD1 mutations affect DNA replication and proofreading functions, leading to increased mutational burden and conditions such as Polymerase Proofreading-Associated Polyposis (PPAP) syndrome. While these mutations increase the risk of cancers such as colorectal, endometrial, and brain cancers, they are also associated with a high tumor mutational burden — making tumors more responsive to immunotherapy.

Product details:
Our FFPE-based POLE-POLD1 Mutation Controls provide highly reliable and consistent standards for molecular assays. Each control contains embedded DNA with clinically relevant variants at ~5% allele frequency, ideal for assay development, validation, and proficiency testing.

Available Variants:

• POLE p.P286R (Exon 9) – Cat. No. D181-001
• POLE p.F367S (Exon 11) – Cat. No. D181-002
• POLE p.V411L (Exon 13, G>C) – Cat. No. D181-003
• POLE p.S459F (Exon 14) – Cat. No. D181-004
• POLD1 p.S478N (Exon 12) – Cat. No. D181-005

Each control provides:

• Target VAF: 5%
• gDNA: ~ 100,000 copies/curl
• DNA mass: ~200 ng/curl

📩 This new product is already receiving strong interest from our customers worldwide. To request a quotation or place an order, please contact us today.